Quantcast

Latest Brain tumor Stories

2014-09-18 23:05:34

Research conducted by a team of neurosurgeons and radiation oncologists from Allegheny Health Network, and presented this week at the American Society for Radiation Oncology annual meeting, has documented improved survival in patients with cancerous brain tumors who undergo both surgical removal of the tumors along with stereotactic radiosurgery. Pittsburgh, PA (PRWEB) September 18, 2014 Research conducted by a team of neurosurgeons and radiation oncologists from Allegheny Health Network...

2014-09-18 12:30:21

ASHEVILLE, N.C., Sept. 18, 2014 /PRNewswire-USNewswire/ -- The Pediatric Brain Tumor Foundation's Starry Night 8.5K is an evening walk/run to help kids battling one of the deadliest forms of childhood cancer. Starry Night Chicago is coming to Arlington International Racecourse on Saturday, Oct. 4. More than 28,000 children in the United States are living with a brain tumor. Each of the 28,000 steps in Starry Night's 8.5K walk/run will shine light on their illness and raise funds...

2014-09-17 08:28:28

ICT-107 Phase II Update Selected for Oral Presentation at Society for Neuro-Oncology Meeting in November; ICT-121 and ICT-140 Programs on Track LOS ANGELES, Sept. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) provides a corporate update on its plans to advance ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM), and on its portfolio of dendritic cell-based vaccines: ICT-121 for patients...

2014-09-16 08:32:04

HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. "DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to announce the initiation of our randomized...

2014-09-16 08:30:30

"PIM" Designation For DCVax-L Is First Step In 2-Step Process for Early Access Approval BETHESDA, Md., Sept. 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that its DCVax-L is the first product to receive formal designation as a "Promising Innovative Medicine" (PIM) under the new "Early Access to Medicines Scheme" (EAMS) launched in the UK...

2014-09-11 12:27:08

Medical Community Members and Locals Honored For Their Tireless Support For The Cause And Ongoing Fight For A Cure WASHINGTON, Sept. 11, 2014 /PRNewswire-USNewswire/ -- Voices Against Brain Cancer is set to host its inaugural annual "Join the Voices! D.C. Walk." On Sunday, September 21, 2014 The National Mall will be filled with individuals, friends, family and loved ones joined together in support of this worthy cause. Registration begins at 8:00 AM with a 9:00 AM start time. The...

2014-09-10 16:26:43

More Than 275 Procedures Performed at Top Medical Centers Across the U.S. PLYMOUTH, Minn., Sept. 10, 2014 /PRNewswire/ -- Monteris Medical announced today that its NeuroBlate(®) System, a minimally invasive robotic laser thermotherapy tool, has now been used by leading surgeons across the U.S. in more than 275 procedures. The NeuroBlate System employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. The NeuroBlate System...

2014-09-09 08:31:48

Intraoperative neurosurgical platforms offer precision and workflow improvement for ablating brain tumors MINNEAPOLIS, Sept. 9, 2014 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that the Company's InSitu(TM) wireless coil and Monteris NeuroBlate(®) laser ablation system have been used together for the first time at a leading United States neuroscience center. This combination brought improved visualization and workflow in removing a...

2014-09-04 23:05:39

Research takes another step closer to clinical trials. Chicago, IL (PRWEB) September 04, 2014 The American Brain Tumor Association (ABTA) Discovery Grant funding of high-risk, high-impact projects continues to be a catalyst for moving innovative treatment concepts closer to the clinic. Recently, Curtana Pharmaceuticals, a privately-held, preclinical stage pharmaceutical company announced that they will continue their OLIG2 inhibitor research—research initially funded by an ABTA...

2014-09-04 08:30:32

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 4, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, will be featured as a presenting company at the SeeThruEquity Fall Microcap Investor Conference. The presentation will take place at 11AM ET on September 11, 2014 at the Convene Times Square in New York City. Jeffrey Bacha, president and CEO of DelMar, will provide an overview of DelMar's ongoing clinical development program...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.